Shaftel, Norman; Halpern, Alfred
February 1958
Angiology;Feb1958, Vol. 9 Issue 1, p34
Academic Journal
Examines the efficacy of quinidine in the treatment of cardiovascular diseases. Contraindication to the use of the drug due to its toxic manifestations; Analysis on the allergic and idiosyncratic reaction of the drug; Response of cardiac patients to cardiovascular therapy using quinidine.


Related Articles

  • ARISE: Succinobucol delivers mixed results in phase 3 trial of patients with ACS.  // Formulary;Jun2007, Vol. 42 Issue 6, p397 

    The article focuses on the findings of the Aggressive Reduction of Inflammation Stops Events (ARISE) trial on the use of succinobucol on acute coronary syndrome (ACS) patients in the U.S. The results were presented during the 56th Annual Scientific Session of the American College of Cardiology...

  • Guidelines program improved adherence among patients with diabetes, ACS. Costa, Samantha; Ellis, Brian; Foster, Melissa; Kalvaitis, Katie; Volansky, Rob // Endocrine Today;Dec2012, Vol. 10 Issue 12, p30 

    The article focuses on the study by Dr. Prakash C. Deedwania and his colleagues at the Veteran Affairs (VA) Central California Health Care System/University of California, San Francisco, which revealed that guideline-based therapy contributed to improvements in most performance measures in acute...

  • High-dose statins are cost-effective compared with conventional-dose statins in patients with acute coronary syndromes.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p80 

    The article presents a study on the cost-efficacy of high-dose statin therapy over conventional-dose statin therapy in patients with acute coronary syndromes (ACSs). It mentions the design, setting and intervention for the study. Hypothetical cohorts of 60-year-old patients with ACS or stable...

  • COMMENTARY: High-dose statins are cost-effective compared with conventional-dose statins in patients with acute coronary syndromes. Alter, David A. // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p80 

    The author reflects on the study on cost-efficacy of high-dose statin therapy over conventional-dose statins in patients with acute coronary syndromes (ACSs). He observes variation between the mechanisms of death of ACS and stable vascular disease. He also notices vagueness in the optimal target...

  • Dual therapy 'last resort' for CHD. Hensler, Paula // GP: General Practitioner;5/3/2004, p27 

    Statin and ezetimibe combination therapy should only be used as a last resort for high-risk coronary heart disease patients, according to general practitioners (GPs) with an interest in cardiology. However, GPs with an interest in cardiology say combination therapy with the new drug should be...

  • Regadenoson. Garnock-Jones, Karly P.; Curran, Monique P. // American Journal of Cardiovascular Drugs;2010, Vol. 10 Issue 1, p65 

    Regadenoson is an adenosine A2A receptor agonist approved for use as a pharmacologic stress agent for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Regadenoson causes a rapid increase in coronary blood flow, which is sustained for a short...

  • Study finds no link between intracerebral hemorrhage and statin use among patients with prior stroke.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p687 

    The article presents a study published online by "Archives of Neurology" which finds that using cholesterol-lowering statin medications in patients who have an ischemic stroke is not associated with intracerebral hemorrhage.

  • Preparation of the Cardiac Patient for Noncardiac Surgery. Flood, Christopher; Fleisher, Lee A. // American Family Physician;3/1/2007, Vol. 75 Issue 5, p656 

    Approximately 20 to 40 percent of patients at high risk of cardiac-related morbidity develop myocardial ischemia perioperatively. The preferred approach to diagnostic evaluation depends on the interactions of patient-specific risk factors, surgery-specific risk factors, and exercise capacity....

  • Rational approaches to the treatment of mixed dyslipidemia.  // Formulary;Oct2008, Vol. 43 Issue 10, p366 

    The article reports on the treatment of patients with coronary heart diseases, including mixed dyslipidemia. According to the author, using optimal statin therapy in targeting low-density lipoprotein (LDL) is an accepted treatment for the disease. However, the author says that combination...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics